ArticleThe American journal of cardiology2010
Circulating levels of endothelial progenitor cell mobilizing factors in the metabolic syndrome.
Article in The American journal of cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02694575 (The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Lung function in elderly subjects with metabolic syndrome and type II diabetes : Data from the Berlin Aging Study II.Zeitschrift fur Gerontologie und Geriatrie · 2025Article
- An Overview of Growth Factors as the Potential Link between Psoriasis and Metabolic Syndrome.Journal of clinical medicine · 2023Review
- Circulating microRNAs and endothelial cell migration rate are associated with metabolic syndrome and fitness level in postmenopausal African American women.Physiological reports · 2019Article
- Exercise and Cardiovascular Progenitor Cells.Comprehensive Physiology · 2019Review
- Systemic Factors During Metabolic Disease Progression Contribute to the Functional Decline of Adipose Tissue-Derived Mesenchymal Stem Cells in Reproductive Aged Females.Frontiers in physiology · 2018Article
- Role of free fatty acids in endothelial dysfunction.Journal of biomedical science · 2017Review
- [Pulmonary function in elderly subjects with metabolic syndrome and type II diabetes : Data from the Berlin Aging Study II].Zeitschrift fur Gerontologie und Geriatrie · 2016Article
- Oxytocin and cardioprotection in diabetes and obesity.BMC endocrine disorders · 2016Review
- Heme-Mediated Induction of CXCL10 and Depletion of CD34+ Progenitor Cells Is Toll-Like Receptor 4 Dependent.PloS one · 2015Article
- Vascular endothelial growth factor from embryonic status to cardiovascular pathology.Reports of biochemistry & molecular biology · 2014Review
- Circulating endothelial progenitor cells in acromegaly.Journal of endocrinological investigation · 2013Article
- Endothelial progenitor cells: a new player in lupus?Arthritis research & therapy · 2012Review
- Dysfunctional endothelial progenitor cells in metabolic syndrome.Experimental diabetes research · 2012Review
- Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension.Hypertension (Dallas, Tex. : 1979) · 2011Review
- Could metabolic syndrome, lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes?Stem cells international · 2011Article
- Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?Vascular pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Endothelial progenitor cells (EPCs) are an emerging biomarker of vascular health. However, there are few data on the biology and mobilizing factors of EPCs in metabolic syndrome (MS). The aim of this study was to assay EPC mobilizing factors, including granulocyte colony-stimulating factor, stem cell factor/c-kit ligand (SCF), vascular endothelial growth factor, and stromal cell-derived factor-1 levels, in patients with MS (n = 36) and age- and gender-matched controls (n = 38). There was a significant reduction of 83% in granulocyte colony-stimulating factor levels in patients with MS. Also, there were decreases in SCF and SCF soluble receptor levels. However, there was no significant difference in stromal cell-derived factor-1 levels, and paradoxically, vascular endothelial growth factor levels were increased, consistent with resistance. In conclusion, in addition to progenitor cell exhaustion as a mechanism for the decrease in EPCs in patients with MS, they also have a mobilization defect, as manifested by decreased levels of granulocyte colony-stimulating factor and SCF, resulting in a decrease in EPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.